{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:24:28Z","timestamp":1789925068011,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ygyno.2019.03.253","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T16:48:02Z","timestamp":1555001282000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population"],"prefix":"10.1016","volume":"154","author":[{"given":"Anna R.","family":"Giuliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar A.","family":"Joura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warner K.","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole-Erik","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne K.","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Ferenczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte M.","family":"Ronnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Stoler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver M.","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Luxembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.03.253_bb0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.28963","article-title":"Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide","volume":"136","author":"Alemany","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0020","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0025","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.ejca.2015.06.001","article-title":"Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions","volume":"51","author":"Serrano","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0030","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1586\/14760584.2015.1089174","article-title":"9-valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV","volume":"14","author":"Pitisuttithum","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0040","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cct.2015.02.009","article-title":"Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine","volume":"42","author":"Luxembourg","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0050","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0055","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1740774514552110","article-title":"A seamless phase IIB\/III adaptive outcome trial: design rationale and implementation challenges","volume":"12","author":"Chen","year":"2015","journal-title":"Clin. Trials"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0065","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/JCM.00236-10","article-title":"Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay","volume":"49","author":"Else","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0070","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1128\/JCM.00235-10","article-title":"Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection","volume":"49","author":"Roberts","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens--part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0085","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/14760584.2017.1383158","article-title":"9-valent human papillomavirus vaccine: a review of the clinical development program","volume":"16","author":"Luxembourg","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0090","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0095","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/ijc.25940","article-title":"Impact of an HPV6\/11\/16\/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16\/18 infection","volume":"129","author":"Haupt","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0100","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Jr., P. Pitisuttithum, D. Tresukosol, J. Monsonego, K. Ault, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0105","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1086\/522864","article-title":"Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection","volume":"196","author":"FUTURE II Study Group","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0110","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0115","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/cid\/cir1036","article-title":"Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study","volume":"54","author":"Swedish","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0120","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.03.253_bb0125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2015.01.551","article-title":"Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial","volume":"137","author":"Monsonego","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ypmed.2016.11.020","article-title":"Cervical cancer screening in women vaccinated against human papillomavirus infection: recommendations from a consensus conference","volume":"98","author":"Giorgi Rossi","year":"2017","journal-title":"Prev. Med."},{"key":"10.1016\/j.ygyno.2019.03.253_bb0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/JCM.02116-14","article-title":"A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results","volume":"53","author":"Schiffman","year":"2015","journal-title":"J. Clin. Microbiol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819304883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819304883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:45:49Z","timestamp":1758771949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819304883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0090825819304883"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.253","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Merck Sharp & Dohme Corp. and the Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}